First-in-class small molecule inhibitor shows promise against pancreatic cancer in preclinical studies
Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the "undruggable" PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic cancer, grow and resist treatment. In laboratory studies, the drug slowed tumor growth, improved survival and enhanced the effects of the chemotherapy drug gemcitabine.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
